Welcome to CAR-T & Cellular Therapy Focus, where you can explore the latest updates in this field by haematological disease and therapy type, showcasing expert interviews and discussions, podcasts and e-learning.

CAR-T and other cellular therapies are at the frontier of hematological malignancy research, offering the potential for paradigm-changing new treatments. Although various questions remain open, it is essential that healthcare professionals understand these therapies, including recognizing and managing their toxicities, and when and how to use them.

View all videos

CAR-T & Cellular Therapy

CAR-T & Cellular Therapy

Welcome to CAR-T & Cellular Therapy Focus, where you can explore the latest updates in this field by haematological disease and therapy type, showcasing expert interviews and discussions, podcasts and e-learning.

CAR-T and other cellular therapies are at the frontier of hematological malignancy research, offering the potential for paradigm-changing new treatments. Although various questions remain open, it is essential that healthcare professionals understand these therapies, including recognizing and managing their toxicities, and when and how to use them.

View all videos

Latest CAR-T and Cellular Therapy Videos

View all videos
CAR-T cells for myeloma: experience from China
He Huang
The role of nurses in apheresis during CAR T-cell therapy
Erik Aerts
CAR-T assessment in the ambulatory care setting
Diana Comerford
Patient monitoring following CAR T-cell therapy
Erik Aerts

View CAR-T and Cellular Therapy Videos by Disease Area

Multiple Myeloma
Lymphoma
ALL
AML
CLL
CAR-T cells for myeloma: experience from China
He Huang
Clinical manufacturing of CAR T-cells
Bruce Levine
Regulatory hurdles in CAR T-cell therapy roll-out
Bruce Levine
Sagar Lonial discusses his top myeloma research picks
Sagar Lonial
View All Videos
CAR T-cell therapy: the patient’s perspective
Bregje Verhoeven
CD19 CAR T-cell therapy for lymphoma
Michael Schmitt
CART19-BE-01 trial: next-generation CAR T-cell therapy for CD19+ R/R leukemia and lymphoma
Valentín Ortiz-Maldonado
Transplantation in the era of CAR T-cell therapy
Julio Delgado
View All Videos
CAR T-cell therapy: the patient’s perspective
Bregje Verhoeven
Transplantation in the era of CAR T-cell therapy
Julio Delgado
CARPALL and AMELIA: ongoing data for CAR-T in ALL
Sara Ghorashian
CAR-T for ALL: access, eligibility & toxicity
Sara Ghorashian
View All Videos
CAR T-cell therapy: AML adverse events and optimization
Elizabeth Budde
CD123 CAR-T therapy for the treatment of AML
Elizabeth Budde
The challenges in treating AML with CAR T-cell therapy
Elizabeth Budde
The future of CAR T-cell therapy for AML
Elizabeth Budde
View All Videos
The role of the advanced nurse practioner in CAR T-cell therapy
Jenai Wilmoth
Regulatory qualification for the EBMT patient registry for CAR T-cell therapy
Christian Chabannon
CAR T-cell therapy: what clinicians need to know about managing the AEs
David Maloney
Challenges after CAR T-cell therapy
David Maloney
View All Videos

View CAR-T and Cellular Therapy Videos by Topic

Nursing
Clinical Practice
Policy
Treatment
Toxicity
Manufacturing
CAR-T assessment in the ambulatory care setting
Diana Comerford
Patient monitoring following CAR T-cell therapy
Erik Aerts
Educating and training nurses involved with CAR T-cell therapy
Diana Comerford
Educational material for HCPs on CAR T-cell therapy
Erik Aertes
View All Videos
Intensive care for CAR-T: bridge to treatment and response
Michael von Bergwelt
Learnings from a CAR-T center: leukapheresis, bridging therapy, toxicities & more
Michael von Bergwelt
CAR-T super users: teams to closely monitor patients receiving CAR T-cells
Bianca Santomasso
Nuances of systemic lymphoma and CNS lymphoma
Bianca Santomasso
View All Videos
CAR T-cell therapy economics in the real world
Duane Schulthess
The importance of registering CAR T-cell patient data
Max Topp
EBMT CAR T-cell priorities
Nicholaus Kroger
The importance of EBMT-EHA in European CAR T-cell therapy
Nicholaus Kroger
View All Videos
CAR-T cells for myeloma: experience from China
He Huang
CAR-T assessment in the ambulatory care setting
Diana Comerford
Patient monitoring following CAR T-cell therapy
Erik Aerts
Educating and training nurses involved with CAR T-cell therapy
Diana Comerford
View All Videos
Improving the manufacturing of CAR T-cells
Alexey Bersenev
Side effects of CAR T-cell therapy
Michael Schmitt
CAR-T for ALL: access, eligibility & toxicity
Sara Ghorashian
The role of the advanced nurse practioner in CAR T-cell therapy
Jenai Wilmoth
View All Videos
The importance of the European Medicines Agency in CAR-T development
Ulrich Jäger
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Anas Younes et al.
Identifying patient subgroups to improve outcome, resistance and toxicity in CAR T
John Rossi
Game-changing drug classes for multiple myeloma
Gareth Morgan
View All Videos

View CAR-T and Cellular Therapy Videos by Therapy Type

CAR T-Cell Therapy
NK-Cell Therapy
CAR-T cells for myeloma: experience from China
He Huang
CAR-T assessment in the ambulatory care setting
Diana Comerford
Patient monitoring following CAR T-cell therapy
Erik Aerts
Educating and training nurses involved with CAR T-cell therapy
Diana Comerford
View All Videos
Are CAR NK-cells the future of CLL therapy?
William Wierda
Immuno-oncology agents for MM: checkpoint inhibitors and NK-cells
Noopur Raje
CAR T-cells vs. CAR NK-cells
William Wierda
10 years of researching NK-cells for MM treatment
Nina Shah
View All Videos

VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals